CD19 and lymphoma: Quantifiable phenotypes associated with pre-infusion PSMA CAR T-cells in mCRPC also shared with CD19 CAR T-cell products in leukemia and lymphoma are potentially actionable by enriching desirable, or eliminating undesirable, cellular populations or functional states during ex vivo manufacturing.